Boundless Bio financials
$2.56−1.92%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 |
| Gross margin | — | — |
| Operating income | -$63.6M | -$73.3M |
| Net income | -$58.2M | -$65.4M |
| Net margin | — | — |
| Diluted EPS | $-2.60 | $-3.85 |
| EBITDA | -$62.3M | -$72.2M |
| Operating cash flow | -$46.7M | -$60.8M |
| Free cash flow | -$47.2M | -$63.4M |
| Diluted shares | 22.4M | 17.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $17.9M | $26.6M |
| Short-term investments | $89.7M | $125.5M |
| Total debt | $0.00 | $0.00 |
| Total assets | $157.1M | $206.4M |
| Total liabilities | $58.4M | $55.8M |
| Shareholders' equity | $98.7M | $150.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology